Evidence for G6PD variant classification from multiplexed functional assays
Authors:
Open Access
- 4 June 2026
- journal article
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
Abstract
Background: G6PD deficiency is one of the most common enzyme deficiencies worldwide, and increases the likelihood of adverse reactions to certain drugs and foods. As availability of routine sequencing and biobanking increases, more variants in G6PD have been identified but not connected to phenotypes, since most G6PD-deficient individuals are asymptomatic until they encounter a trigger. This is further complicated since over 60% of 1,559 known genetic variants in G6PD are variants of uncertain significance and thus cannot guide drug prescribing and dosing. Results: To resolve which variants are clinically meaningful and avoid harm from adverse drug reactions, we conducted two high-throughput functional assays: one for G6PD activity, and one for abundance. We measured the function of 9,504 missense, nonsense, and synonymous G6PD variants. The patterns of variant effect on activity and abundance confirmed the importance of structural NADP + for G6PD activity and abundance, and G6PD dimerization for G6PD activity. Based on the ability of our functional assay scores to accurately classify G6PD variants of known clinical effect, we generated evidence that 4,773 missense variants contribute to G6PD deficiency and 2,295 are unlikely to contribute to G6PD deficiency. Conclusions: Our data can be used to deepen our understanding of G6PD as a protein, and to close the gap in classification for variants of uncertain significance to improve implementation of genetic medicine for G6PD deficiency.Keywords
Funding Information
- National Human Genome Research Institute (T32 HG000035)
- National Human Genome Research Institute (UM1 HG011969)
- National Institute of General Medical Sciences (F32 GM143852)
- National Institute of General Medical Sciences (R01 GM132162)
- Momental Foundation
- National Cancer Institute (P30 CA015704)
- Pharmacogenomics Global Research Network
- University of Washington William H. Gates III Endowed Chair in Biomedical Sciences
This publication has 55 references indexed in Scilit:
- Insights on improving accessibility and usability of functional data to unlock their potential for variant interpretationThe American Journal of Human Genetics, 2025
- Functional interpretation, cataloging, and analysis of 1,341 glucose-6-phosphate dehydrogenase variantsThe American Journal of Human Genetics, 2023
- Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteriaThe American Journal of Human Genetics, 2022
- Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD GenotypeClinical Pharmacology & Therapeutics, 2022
- Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTENThe American Journal of Human Genetics, 2021
- Massively parallel characterization of CYP2C9 variant enzyme activity and abundanceThe American Journal of Human Genetics, 2021
- Small‐Molecule Activators of Glucose‐6‐phosphate Dehydrogenase (G6PD) Bridging the Dimer InterfaceChemMedChem, 2019
- REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense VariantsThe American Journal of Human Genetics, 2016
- The Efficiency of Translation Termination is Determined by a Synergistic Interplay Between Upstream and Downstream Sequences inSaccharomyces cerevisiaeJournal of Molecular Biology, 1995
- Yeast vectors for the controlled expression of heterologous proteins in different genetic backgroundsGene, 1995